Company: XOMAP
Filing Date: 2025-10-03
Form Type: 424B5
Source: 0001193125-25-230383
Chunk: 3

Company: XOMA Royalty Corp
Filing Date: 2025-10-03
Form: 424B5
Chunk 3
---
 incorporated by reference into this prospectus supplement and the accompanying prospectus. This summary is not complete and does not contain all of the information that you should consider before deciding whether to invest in our Common Stock. For a more complete understanding of our Company and this offering, we encourage you to read and consider carefully the more detailed information in this prospectus supplement and the accompanying prospectus, including the information incorporated by reference in this prospectus supplement and the accompanying prospectus, and the information included in any free writing prospectus that we have authorized for use in connection with this offering, including the information under the heading “Risk Factors” in this prospectus supplement beginning on page S-6,and under similar headings in the other documents that are filed after the date hereof and incorporated by reference into this prospectus supplement and the accompanying prospectus.

Company Overview

We are a biotech
royalty aggregator with a sizable portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. Our portfolio
was built through the acquisition of rights to future milestone payments, royalties, and commercial payments, since our royalty aggregator business model was implemented in 2017. These acquisitions build upon
out-licensing agreements for proprietary products and platforms held within our portfolio.

Our drug royalty
aggregator business is primarily focused on early to mid-stage clinical assets in Phase 1 and 2 development, which we believe have significant commercial sales potential and that are licensed to well-funded
partners with established expertise in developing and commercializing drugs. We also acquire milestone and royalty revenue streams on late-stage or commercial assets that are designed to address unmet markets or have a therapeutic advantage over
other treatment options, and have long duration of market exclusivity. We expect most of our future income and revenue to be based on payments we may receive for milestones and royalties associated with these assets as well as the periodic
recognition of income under the Effective Interest Rate method.

Corporation Information

We were incorporated in Delaware in 1981 and became a Bermuda-exempted company in December 1998. Effective December 31, 2011, we changed our jurisdiction
of incorporation from Bermuda to Delaware and changed our name from XOMA Ltd. to XOMA Corporation. Effective July 10, 2024, we changed our name from XOMA Corporation to XOMA Royalty Corporation. Effective May 30, 2025, we changed our
jurisdiction of incorporation from Delaware to Nevada.

Our principal executive offices are located